Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Core Insights - Eledon Pharmaceuticals has made significant progress in 2025, particularly with the tegoprubart clinical programs in kidney allotransplantation, islet transplantation, and xenotransplantation, showing promising results in safety and efficacy [2][3] Group 1: Clinical Trial Results - The Phase 2 BESTOW trial demonstrated tegoprubart's favorable safety and tolerability profile, reducing toxicities associated with tacrolimus, with a kidney function eGFR of 69 mL/min/1.73 m² at 12 months, the highest reported in larger trials [3] - The efficacy failure composite endpoint for tegoprubart was 22.2% compared to 17.2% for tacrolimus, indicating non-inferiority [3] - Preliminary results from six type 1 diabetes patients treated with tegoprubart post-islet transplantation showed all achieved insulin independence, with three remaining insulin-free for over a year [3] Group 2: Regulatory and Development Plans - The company plans to engage with regulatory authorities, including the FDA, to advance tegoprubart into Phase 3 development, aiming to provide a safer alternative to tacrolimus-based immunosuppression [2][4] - Anticipated milestones for 2026 include presenting 24-month data from a Phase 1 extension study at the American Society of Transplant Surgeons Winter Symposium [4][7] Group 3: Financial Developments - Eledon completed a $57.5 million financing, expected to support operations into the second quarter of 2027 [3][4]